Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MRG003 in EGFR-positive, HER2-negative advanced gastric cancer
CTR20212039Phase 2Terminated
- Sponsor
- Hangzhou Miracogen
- Start
- Dec 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Hangzhou Miracogen. Started Dec 2021; status: terminated.
02
Drugs
becotatug vedotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20212039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212039.